Kovaltry (Antihemophilic factor [recombinant]) for Hemophilia

Overview
Kovaltry is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A. Kovaltry can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Kovaltry is Antihemophilic factor (recombinant).

Kovaltry is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Kovaltry is given as an intravenous injection.

Kovaltry comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Kovaltry lists common side effects including fever, headache, and itching.

Rare but serious side effects listed for Kovaltry include life-threatening hypersensitivity reactions and the development of inhibitors.

For more details about this treatment, visit:

Kovaltry.com
https://www.kovaltry-us.com/